Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • Universal driving restrictions...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Bibliographic Details
Published in:Blood Advances
Main Authors: Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Djordje Atanackovic, Shebli Atrash, Veronika Bachanova, Amer M. Beitinjaneh, Evguenia Bhurtel, Omar Castaneda Puglianini, Saurabh Chhabra, Kara I. Cicero, James A. Davis, Binod Dhakal, Danai Dima, Christopher J. Ferreri, Peter A. Forsberg, Ciara L. Freeman, Megan M. Herr, Tania Jain, Murali Janakiram, Jack Khouri, Mehmet H. Kocoglu, Anupama Kumar, Yuxin Liu, Frederick Locke, Joseph P. McGuirk, Lekha Mikkilineni, Omar Nadeem, Ricardo D. Parrondo, Oren Pasvolsky, Lauren C. Peres, Sneha Purvey, Shahzad Raza, Ran Reshef, Shambavi Richard, Adriana C. Rossi, Douglas W. Sborov, Leyla Shune, Charlotte B. Wagner, Saurabh S. Zanwar, Surbhi Sidana, Krina K. Patel, Doris K. Hansen, Shaji K. Kumar, Yi Lin, Thomas G. Martin, Peter M. Voorhees, Larry D. Anderson, Jr, Andrew J. Cowan, Gurbakhash Kaur
Format: Article
Language:English
Published: Elsevier 2025-05-01
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925001715
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.sciencedirect.com/science/article/pii/S2473952925001715

Similar Items

  • Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
    by: Saurabh Zanwar, et al.
    Published: (2024-06-01)
  • Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
    by: Aimaz Afrough, et al.
    Published: (2024-04-01)
  • Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience
    by: Hamza Hashmi, et al.
    Published: (2023-10-01)
  • Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
    by: Christopher J. Ferreri, et al.
    Published: (2023-08-01)
  • Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment
    by: Surbhi Sidana, et al.
    Published: (2023-09-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs